NEW YORK, March 03, 2016 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) announced that trading of Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX) commenced on The Nasdaq Stock Market on March 3, 2016.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/dbf86fa3-28f2-4c4f-b539-dcbae1c5c80d
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body’s immune response to tumors. Syndax is developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer.
“Today marks a major milestone for Syndax as we celebrate our initial public offering on Nasdaq,” said Briggs Morrison, M.D., Chief Executive Officer at Syndax. “The Syndax team is determined to realize a future in which people with cancer live longer and better than ever before.”
“Nasdaq is proud to be the listing exchange of choice for companies committed to innovation and providing breakthrough solutions that transform our lives in all aspects,” said Nelson Griggs, Executive Vice President, Listing Services, Nasdaq. “We are excited to support the growth of Syndax as they continue their clinical development programs and offer advanced cancer treatment options for patients.”
Nasdaq has been the strategic listing partner for companies in growth sectors including healthcare, technology and consumer. In 2015, approximately 90 percent of all U.S. healthcare companies listed with Nasdaq and 95 percent of biotechnology companies. 100 percent of all IPOs in the U.S. in 2016 have listed at Nasdaq.
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information about the company is provided by the company or comes from the company’s public filings and is not independently verified by Nasdaq. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
About Syndax Pharmaceuticals, Inc.
Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC). Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body’s immune response to tumors. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Merck KGaA, Darmstadt, Germany and Pfizer Inc. in ovarian cancer. Syndax is also developing entinostat as a combination therapeutic in a Phase 3 clinical trial that is being conducted with ECOG-ACRIN for advanced hormone receptor positive breast cancer. For more information on Syndax please visit www.syndax.com.
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of approximately $9.6 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com
- NDAQG -